Weber, J.Del Vecchio, M.Mandala, M.Gogas, H.Arance Fernandez, A. M.Dalle, S.Cowey, C. L.Schenker, M.Grob, J-J.Sileni, V. ChiarionMarquez-Rodas, I.Butler, M. O.Maio, M.Middleton, M.de la Cruz Merino, L.Lobo, M.de Pril, V.Larkin, J.Ascierto, P. A.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/27550enAdjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238conference outputopen access10.1016/j.annonc.2020.08.12001569-8041http://www.annalsofoncology.org/article/S0923753420411962/pdf573469101364